Complete financial analysis of Johnson & Johnson (JNJ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Johnson & Johnson, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- China National Culture Group Limited (0745.HK) Income Statement Analysis – Financial Results
- Juroku Financial Group,Inc. (7380.T) Income Statement Analysis – Financial Results
- Spin Master Corp. (TOY.TO) Income Statement Analysis – Financial Results
- Public Joint-Stock Company PROTEK (PRTK.ME) Income Statement Analysis – Financial Results
- Air Lease Corporation (AL-PA) Income Statement Analysis – Financial Results
Johnson & Johnson (JNJ)
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B | 70.07B | 74.33B | 71.31B | 67.22B | 65.03B | 61.59B | 61.90B | 63.75B | 61.10B | 53.32B | 50.51B | 47.35B | 41.86B | 36.30B | 33.00B | 29.14B | 27.47B | 23.66B | 22.63B | 21.62B | 18.84B | 15.73B | 14.14B | 13.75B | 12.45B | 11.23B | 9.76B | 9.00B | 8.01B | 7.00B | 6.42B |
| Cost of Revenue | 26.55B | 24.60B | 23.40B | 28.43B | 27.56B | 27.09B | 25.35B | 21.69B | 21.54B | 22.75B | 22.34B | 21.66B | 20.36B | 18.79B | 18.45B | 18.51B | 17.75B | 15.06B | 13.95B | 13.42B | 12.18B | 10.45B | 9.54B | 7.35B | 7.00B | 6.19B | 6.09B | 6.01B | 5.38B | 4.58B | 4.17B | 4.12B | 3.71B | 3.46B | 3.07B | 2.90B | 2.60B | 2.35B | 2.34B |
| Gross Profit | 58.61B | 55.39B | 55.34B | 54.16B | 54.50B | 54.49B | 51.10B | 50.21B | 48.54B | 51.59B | 48.97B | 45.57B | 44.67B | 42.80B | 43.45B | 45.24B | 43.34B | 38.27B | 36.56B | 33.93B | 29.69B | 25.85B | 23.47B | 21.79B | 20.47B | 17.47B | 16.54B | 15.61B | 13.46B | 11.16B | 9.96B | 9.64B | 8.74B | 7.77B | 6.69B | 6.10B | 5.41B | 4.65B | 4.08B |
| Gross Profit Ratio | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.84% | 69.84% | 69.27% | 69.40% | 68.67% | 67.78% | 68.69% | 69.49% | 70.20% | 70.96% | 70.95% | 71.76% | 72.38% | 71.65% | 70.91% | 71.22% | 71.11% | 74.79% | 74.53% | 73.83% | 73.11% | 72.21% | 71.46% | 70.92% | 70.48% | 70.06% | 70.19% | 69.17% | 68.58% | 67.77% | 67.52% | 66.37% | 63.50% |
| Research & Development | 15.05B | 14.14B | 14.28B | 12.34B | 11.36B | 10.78B | 10.55B | 9.10B | 9.05B | 8.49B | 8.18B | 7.67B | 7.55B | 6.84B | 7.17B | 7.76B | 7.68B | 7.13B | 6.31B | 5.20B | 4.68B | 3.96B | 3.59B | 2.93B | 2.60B | 2.27B | 2.14B | 0.00 | 0.00 | 1.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.11B | 19.05B | 20.12B | 22.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.11B | 19.05B | 20.12B | 22.08B | 22.18B | 22.54B | 21.42B | 19.95B | 21.20B | 21.95B | 21.83B | 20.87B | 20.97B | 19.42B | 19.80B | 21.49B | 20.45B | 17.43B | 16.88B | 15.86B | 14.13B | 12.22B | 11.99B | 10.88B | 10.50B | 8.91B | 8.72B | 10.30B | 9.10B | 6.35B | 6.95B | 6.80B | 6.08B | 5.30B | 4.62B | 4.30B | 3.85B | 3.39B | 2.99B |
| Other Expenses | 0.00 | 500.00M | -526.00M | -2.90B | -2.53B | -1.41B | -183.00M | -484.00M | 2.06B | 70.00M | -2.50B | -1.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.56B | 33.18B | 34.40B | 34.42B | 33.53B | 33.32B | 31.97B | 29.04B | 30.25B | 30.45B | 30.01B | 28.53B | 28.52B | 26.27B | 26.97B | 29.25B | 28.13B | 24.56B | 23.19B | 21.06B | 18.82B | 16.17B | 15.58B | 15.32B | 14.55B | 12.42B | 11.92B | 11.31B | 9.95B | 8.35B | 7.57B | 7.36B | 6.57B | 5.78B | 5.03B | 4.70B | 4.20B | 3.66B | 3.24B |
| Cost & Expenses | 61.81B | 57.78B | 57.80B | 62.85B | 61.09B | 60.41B | 57.33B | 50.73B | 51.79B | 53.19B | 52.36B | 50.19B | 48.88B | 45.06B | 45.42B | 47.76B | 45.88B | 39.62B | 37.14B | 34.49B | 30.99B | 26.62B | 25.12B | 22.66B | 21.55B | 18.61B | 18.01B | 17.32B | 15.33B | 12.93B | 11.74B | 11.48B | 10.28B | 9.24B | 8.10B | 7.60B | 6.80B | 6.02B | 5.58B |
| Interest Income | 1.26B | 490.00M | 53.00M | 111.00M | 357.00M | 611.00M | 385.00M | 368.00M | 128.00M | 67.00M | 74.00M | 64.00M | 91.00M | 107.00M | 90.00M | 361.00M | 452.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 772.00M | 276.00M | 183.00M | 201.00M | 318.00M | 1.01B | 934.00M | 726.00M | 552.00M | 533.00M | 482.00M | 532.00M | 571.00M | 348.00M | 451.00M | 435.00M | 296.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.49B | 6.97B | 7.39B | 7.23B | 7.01B | 6.93B | 5.64B | 3.75B | 3.75B | 3.90B | 4.10B | 3.67B | 3.16B | 2.94B | 2.77B | 2.83B | 2.78B | 2.18B | 2.09B | 2.12B | 1.87B | 1.66B | 1.61B | 1.52B | 1.44B | 1.25B | 1.07B | 1.01B | 857.00M | 724.00M | 617.00M | 560.00M | 493.00M | 474.00M | 414.00M | 391.00M | 356.00M | 275.20M | 250.50M |
| EBITDA | 23.73B | 27.17B | 30.93B | 27.50B | 28.27B | 28.10B | 24.54B | 24.92B | 22.12B | 25.03B | 23.16B | 17.96B | 16.05B | 20.35B | 18.96B | 20.20B | 16.36B | 15.77B | 15.61B | 15.02B | 13.27B | 11.82B | 9.78B | 8.08B | 7.59B | 6.96B | 5.62B | 5.46B | 4.42B | 3.58B | 2.93B | 2.78B | 2.65B | 2.63B | 2.08B | 1.70B | 1.47B | 1.79B | 985.40M |
| EBITDA Ratio | 27.86% | 37.71% | 35.38% | 29.27% | 26.96% | 27.64% | 25.95% | 30.16% | 27.15% | 28.68% | 27.40% | 27.07% | 29.93% | 26.84% | 27.51% | 27.84% | 32.86% | 29.58% | 30.91% | 31.72% | 31.71% | 32.57% | 29.63% | 27.73% | 27.64% | 29.41% | 24.81% | 25.24% | 23.45% | 22.72% | 20.73% | 20.24% | 21.32% | 23.45% | 21.33% | 18.88% | 18.29% | 25.50% | 15.35% |
| Operating Income | 23.41B | 23.19B | 20.47B | 16.95B | 15.12B | 15.62B | 14.20B | 17.93B | 15.28B | 17.42B | 15.43B | 14.53B | 16.31B | 13.59B | 14.26B | 14.92B | 17.30B | 13.60B | 13.52B | 12.90B | 11.40B | 10.16B | 8.18B | 6.57B | 6.15B | 5.71B | 4.55B | 4.45B | 3.56B | 2.85B | 2.31B | 2.22B | 2.16B | 2.16B | 1.67B | 1.31B | 1.11B | 1.51B | 734.90M |
| Operating Income Ratio | 27.49% | 28.99% | 26.00% | 20.52% | 18.42% | 19.15% | 18.57% | 24.94% | 21.80% | 23.44% | 21.64% | 21.61% | 25.08% | 22.06% | 23.03% | 23.40% | 28.31% | 25.50% | 26.76% | 27.24% | 27.24% | 27.99% | 24.77% | 22.53% | 22.38% | 24.14% | 20.10% | 20.57% | 18.90% | 18.12% | 16.37% | 16.16% | 17.36% | 19.23% | 17.09% | 14.53% | 13.84% | 21.57% | 11.44% |
| Total Other Income/Expenses | -8.35B | -2.85B | -1.77B | -3.24B | 2.21B | 2.38B | -1.22B | -1.09B | 907.00M | -574.00M | 38.00M | -3.26B | -3.79B | 420.00M | -908.00M | 760.00M | -1.93B | 990.00M | 137.00M | 482.00M | -563.00M | -387.00M | -277.00M | 303.00M | -108.00M | -846.00M | -46.00M | -270.00M | -194.00M | -126.00M | -62.00M | -70.00M | -126.00M | -369.00M | -147.00M | -8.00M | -16.00M | -592.80M | 164.30M |
| Income Before Tax | 15.06B | 19.36B | 19.18B | 16.50B | 17.33B | 18.00B | 17.67B | 19.80B | 19.20B | 20.56B | 15.47B | 13.78B | 12.36B | 16.95B | 15.76B | 16.93B | 13.28B | 14.59B | 13.66B | 12.84B | 10.31B | 9.29B | 7.90B | 6.62B | 5.75B | 4.27B | 4.58B | 4.03B | 3.32B | 2.68B | 2.33B | 2.21B | 2.04B | 1.62B | 1.51B | 1.40B | 1.19B | 390.80M | 899.20M |
| Income Before Tax Ratio | 17.69% | 24.20% | 24.36% | 19.98% | 21.12% | 22.06% | 23.12% | 27.55% | 27.39% | 27.66% | 21.69% | 20.49% | 19.01% | 27.52% | 25.45% | 26.56% | 21.74% | 27.36% | 27.03% | 27.11% | 24.62% | 25.60% | 23.93% | 22.73% | 20.94% | 18.05% | 20.22% | 18.65% | 17.60% | 17.04% | 16.49% | 16.05% | 16.37% | 14.45% | 15.52% | 15.51% | 14.89% | 5.58% | 14.00% |
| Income Tax Expense | 1.74B | 2.99B | 1.38B | 1.78B | 2.21B | 2.70B | 16.37B | 3.26B | 3.79B | 4.24B | 1.64B | 3.26B | 2.69B | 3.61B | 3.49B | 3.98B | 2.71B | 3.53B | 3.25B | 4.33B | 3.11B | 2.69B | 2.23B | 1.82B | 1.59B | 1.21B | 1.27B | 1.15B | 914.00M | 675.00M | 545.00M | 582.00M | 577.00M | 480.00M | 432.00M | 422.00M | 360.00M | 61.30M | 285.50M |
| Net Income | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B | 13.83B | 10.85B | 9.67B | 13.33B | 12.27B | 12.95B | 10.58B | 11.05B | 10.41B | 8.51B | 7.20B | 6.60B | 5.67B | 4.80B | 4.17B | 3.06B | 3.30B | 2.89B | 2.40B | 2.01B | 1.79B | 1.03B | 1.46B | 1.14B | 1.08B | 974.00M | 833.00M | 329.50M | 613.70M |
| Net Income Ratio | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% | 20.73% | 20.61% | 17.97% | 17.19% | 18.17% | 17.17% | 16.47% | 15.17% | 12.93% | 14.60% | 13.35% | 12.75% | 12.75% | 12.64% | 7.49% | 11.74% | 10.18% | 11.09% | 10.82% | 10.40% | 4.71% | 9.56% |
| EPS | 13.88 | 6.86 | 7.93 | 5.59 | 5.74 | 5.75 | 0.48 | 6.08 | 5.57 | 5.86 | 4.90 | 3.91 | 3.54 | 4.86 | 4.45 | 4.67 | 3.67 | 3.76 | 3.38 | 2.75 | 2.42 | 2.20 | 1.87 | 1.65 | 1.43 | 1.08 | 1.24 | 1.09 | 0.93 | 0.78 | 0.69 | 0.17 | 0.55 | 0.43 | 0.41 | 0.36 | 0.31 | 0.12 | 0.21 |
| EPS Diluted | 13.73 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 | 5.93 | 5.48 | 5.70 | 4.81 | 3.86 | 3.49 | 4.78 | 4.40 | 4.57 | 3.63 | 3.73 | 3.35 | 2.74 | 2.29 | 2.16 | 1.84 | 1.61 | 1.39 | 1.06 | 1.21 | 1.09 | 0.93 | 0.78 | 0.68 | 0.16 | 0.54 | 0.43 | 0.40 | 0.35 | 0.31 | 0.12 | 0.21 |
| Weighted Avg Shares Out | 2.53B | 2.61B | 2.63B | 2.63B | 2.63B | 2.66B | 2.68B | 2.71B | 2.76B | 2.78B | 2.82B | 2.78B | 2.72B | 2.74B | 2.76B | 2.81B | 2.88B | 2.94B | 2.98B | 2.97B | 2.97B | 3.00B | 3.03B | 2.99B | 2.99B | 2.78B | 2.67B | 2.66B | 2.58B | 2.57B | 2.61B | 2.63B | 2.66B | 2.66B | 2.67B | 2.74B | 2.73B | 2.75B | 2.92B |
| Weighted Avg Shares Out (Dil) | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B | 2.81B | 2.86B | 2.88B | 2.81B | 2.78B | 2.79B | 2.79B | 2.84B | 2.91B | 2.96B | 3.00B | 2.99B | 3.14B | 3.05B | 3.08B | 3.10B | 3.07B | 2.83B | 2.74B | 2.73B | 2.58B | 2.61B | 2.63B | 2.63B | 2.71B | 2.69B | 2.71B | 2.78B | 2.73B | 2.75B | 2.92B |
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied SAVANNAH, Ga. , Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ)...
Johnson & Johnson stock rises on Q3 sales beat and guidance raise
Johnson & Johnson shares rose 0.7% in premarket trades Tuesday after the drugmaker reported better-than-expected third-quarter sales and raised full-year revenue guidance.
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company's common stock. The dividend is payable on...
J&J lifts profit and sales forecasts, beats Wall Street expectations
Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and quarterly results that beat Wall Street expectations.
Johnson & Johnson Reports Q3 2024 Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson's strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,”...
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson JNJ will release earnings results for its third quarter before the opening bell on Tuesday, Oct. 15.
Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals
Johnson & Johnson JNJ is set to announce its third quarter earnings on Oct. 15 before the market opens. Wall Street is expecting the pharmaceutical and healthcare giant to post earnings per share (EPS) of $2.21 and revenue of $22.16...
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
The size of the pharmaceutical industry in the U.S. in 2023 was estimated to be nearly $575 billion, with an anticipated compound growth rate of about 5.5% through 2030. This key component of the healthcare sector includes both small biotech...
Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth
Johnson & Johnson's Q3 2024 earnings report will highlight its MedTech division, driven by strategic acquisitions and R&D investments in cardiovascular and orthopedic solutions. Despite lagging behind the S&P in price growth, JNJ offers a solid income investment with a...
Source: https://incomestatements.info
Category: Stock Reports